Test Price
2,800 AED✅ Home Collection Available
DNMT3B Gene Immunodeficiency‑Centromeric Instability‑Facial Anomalies Syndrome Type 1 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified NGS Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Telephonic Post‑Test Clinical Guidance in Result Interpretation.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The DNMT3B Gene Genetic Test delivers a definitive molecular diagnosis for patients with suspected Immunodeficiency‑Centromeric Instability‑Facial Anomalies Syndrome Type 1 (ICF1), facilitating precise clinical management and targeted genetic counselling.
| Feature | Our Test (DNMT3B NGS) | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Precision | 100% coverage of all DNMT3B exons with >99.9% base‑level accuracy | WES may miss deep intronic or regulatory variants; average coverage varies |
| Methodology | Targeted NGS (Hybridization Capture + Illumina Sequencing, validated LC‑MS/MS orthogonal confirmation) | Whole Exome capture with lower read depth per gene; bioinformatic filtering required |
| Speed | Turnaround time 3–4 Weeks | Often 6–8 Weeks with longer interpretation queue |
Physician Insight & Safety Protocols
“As a DHA‑licensed Consultant in Medical Genetics, I emphasize that the NGS result—despite its high diagnostic accuracy—must be correlated with the patient’s full immunological profile and physical dysmorphology by a qualified specialist. For paediatric cases, obtaining informed parental consent is mandatory under UAE law. Do not alter corticosteroid or immunosuppressive therapy based solely on the genetic report without a dedicated specialist consultation.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Clinical Advisory Notice
⚠️ Do not discontinue prescribed medication without consulting your doctor.
Patient Safety – Exclusion Criteria & Red Flags
- Exclusion: Recent allogeneic blood transfusion (< 4 weeks) – may contaminate germline DNA with donor cells; postpone collection.
- Exclusion: Known haematologic malignancy with circulating blast cells may cause somatic interference – pre‑test consultation with the laboratory is required.
- Red Flag: If the patient is a minor, valid parental/guardian consent is mandatory under Federal Decree-Law No. 4 of 2016 on Medical Liability.
- ER Warning: This test is not for acute diagnosis. If the patient presents with severe infection, very low immunoglobulins, or respiratory distress, seek immediate emergency care and defer genetic testing until stabilization.
Patient FAQ & Clinical Guidance
1. What does the DNMT3B NGS test detect and how accurate is it?
The test sequences the entire DNMT3B gene using next‑generation sequencing to detect point mutations, small indels, and copy‑number variants with 99.9% diagnostic sensitivity. It covers all coding exons and splice‑site regions, providing a definitive molecular diagnosis for ICF syndrome type 1 when clinical symptoms align. Our ISO‑accredited laboratory uses orthogonal LC‑MS/MS validation to ensure no false‑positive calls, meeting DHA and international standards.
2. How is the sample collected and when will I receive results?
A trained phlebotomist collects 2–5 mL of whole blood in an EDTA tube during a VIP home visit (8 AM‑11 PM) or at our DHA‑licensed facility. We also accept dried blood spots (FTA card) or previously extracted DNA if properly preserved. Turnaround time is 3 to 4 Weeks from receipt of a properly consented sample. Expedited reporting can be arranged on a compassionate basis for critically ill children—contact our WhatsApp support.
3. Is genetic counselling included and what happens after the test?
A mandatory pre‑test genetic counselling session is included to draw a detailed pedigree and explain the test’s implications. After results are released, a telephonic post‑clinical guidance session with a DHA‑licensed geneticist is provided to help interpret findings and plan follow‑up, including family screening and reproductive options. All genetic data is stored in compliance with UAE PDPL and DHAC privacy regulations.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Healthcare Compliance
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Federal Decree-Law No. 4 of 2016 on Medical Liability.
- DHA Facility License: 1143 | ISO 9001:2015 Certified.
Clinical & Logistical Metadata
| Test Name | DNMT3B Gene Immunodeficiency‑Centromeric Instability‑Facial Anomalies Syndrome Type 1 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Dried Blood Spot (FTA Card), or Extracted DNA |
| Methodology Used | Targeted NGS (Hybridization Capture + Illumina Sequencing) |
| ICD-10-CM Code | D81.8, Q87.8 |
| LOINC Code | 81261-6 |
| DHA Facility License & Address | License No: 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians